NL0011323407

Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse

This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse

This is a joint press release by Sanofi (“Sanofi“) and Kiadis Pharma N.V. (“Kiadis“), pursuant to the provisions of Section

This is a press release by Kiadis Pharma N.V. (Kiadis), pursuant to the provisions of Sections 5 paragraphs 4 and

~Five presentations related to Kiadis’ K-NK cell therapy platform will be presented at the 62nd American Society of Hematology (ASH)

This is a joint press release by Sanofi (“Sanofi“) and Kiadis Pharma N.V. (“Kiadis“), pursuant to the provisions of Section

Amsterdam, The Netherlands, November 24, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a